The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)
Open accessAbstract
Purpose Several professional societies have published guidelines for the clinical interpretation of somatic variants, which specifically address diagnostic, prognostic, and therapeutic implications. While these guidelines for the clinical interpretation of variants include data types that may be used to determine the oncogenicity of a variant (e.g., population frequency, functional and in silico data or somatic frequency), they do not provide a direct, systematic, and comprehensive set of standards and rules to classify the oncogenicity of a somatic variant. This insufficient guidance leads to inconsistent classification of rare somatic variants in cancer, generates variability in their clinical interpretation and importantly impacts patient care. Therefore, it’s essential to address this unmet need. Methods Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group and ClinGen Germline/Somatic Variant Subcommittee, the Cancer Genomics Consortium (CGC), and the Variant Interpretation for Cancer Consortium (VICC) used a consensus approach to develop a Standard Operating Procedure (SOP) for the classification of oncogenicity of somatic variants. Results This comprehensive SOP has been developed to improve consistency in somatic variant classification, and has been validated on 94 somatic variants in ten common cancer-related genes. Conclusion The comprehensive SOP is now available for classification of oncogenicity of a somatic variant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
CADD: predicting the deleteriousness of variants throughout the human genome
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J., & Kircher, M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1016 · Cited by 3,534
Predicting splicing from primary sequence with deep learning
Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J. F., Darbandi, S. F., Knowles, D., Li, Y. I., Kosmicki, J. A., Arbelaez, J., Cui, W., Schwartz, G. B., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.015 · Cited by 2,853
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Self-citationPROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels
Choi, Y., & Chan, A. P. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv195 · Cited by 2,549
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Self-citationHighly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Self-citationRecommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion
Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L., Biesecker, L. G., Harrison, S. M., & ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI) (2018) · Human Mutation · doi:10.1002/humu.23626 · Cited by 885
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Self-citationChang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Rentzsch, P., Schubach, M., Shendure, J., & Kircher, M. (2021) · Genome Medicine · doi:10.1186/s13073-021-00835-9 · Cited by 640
On behalf of the Clinical Genome Resource Sequence Variant Interpretation Working Group, Brnich, S. E., Abou Tayoun, A. N., Couch, F. J., Cutting, G. R., Greenblatt, M. S., Heinen, C. D., Kanavy, D. M., Luo, X., McNulty, S. M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-019-0690-2 · Cited by 636
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2010) · Nature · doi:10.1038/nature09132 · Cited by 613
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562
PHAST and RPHAST: phylogenetic analysis with space/time models
Hubisz, M. J., Pollard, K. S., & Siepel, A. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbq072 · Cited by 490
Accelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Bhattarai, T. S., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S., Kandoth, C., Penson, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 409
Self-citationFitting a naturally scaled point system to the ACMG/AMP variant classification guidelines
Tavtigian, S. V., Harrison, S. M., Boucher, K. M., & Biesecker, L. G. (2020) · Human Mutation · doi:10.1002/humu.24088 · Cited by 358
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
McLeod, C., Gout, A. M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S. W., Macias, M., Birch, K., Finkelstein, D., Sunny, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1230 · Cited by 259
Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines
Ghosh, R., Oak, N., & Plon, S. E. (2017) · Genome biology · doi:10.1186/s13059-017-1353-5 · Cited by 233
Self-citationCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214
Mercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
Smith, G., Bounds, R., Wolf, H., Steele, R. J. C., Carey, F. A., & Wolf, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605534 · Cited by 174
Updated recommendation for the benign stand‐alone ACMG/AMP criterion
Ghosh, R., Harrison, S. M., Rehm, H. L., Plon, S. E., Biesecker, L. G., & on behalf of ClinGen Sequence Variant Interpretation Working Group (2018) · Human Mutation · doi:10.1002/humu.23642 · Cited by 173
Self-citationGene‐specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel
Mester, J. L., Ghosh, R., Pesaran, T. F., Huether, R., Karam, R., Hruska, K. S., Costa, H. A., Lachlan, K. L., Ngeow, J. Y. Y., Barnholtz‐Sloan, J. S., et al. (2018) · Human Mutation · doi:10.1002/humu.23636 · Cited by 169
Self-citationRehder, C. W., Bean, L. J., Bick, D. P., Chao, E., Chung, W. K., Das, S., O’Daniel, J. M., Rehm, H. L., Shashi, V., & Vincent, L. M. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01139-4 · Cited by 169
Integrated Informatics Analysis of Cancer-Related Variants
Pagel, K. A., Kim, R., Moad, K., Busby, B., Zheng, L., Tokheim, C. J., Ryan, M., & Karchin, R. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00132 · Cited by 168
Self-citationSpecifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
Fortuno, C., Lee, K., Olivier, M., Pesaran, T., Mai, P. L., Andrade, K. C., Attardi, L. D., Crowley, S., Evans, D. G., Feng, B., et al. (2021) · Human Mutation · doi:10.1002/humu.24152 · Cited by 167
Self-citationA harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Variant Interpretation for Cancer Consortium, Wagner, A. H., Walsh, B., Mayfield, G., Tamborero, D., Sonkin, D., Krysiak, K., Deu-Pons, J., Duren, R. P., Gao, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0603-8 · Cited by 164
Self-citationDouville, C. B., Masica, D. L., Stenson, P. D., Cooper, D. N., Gygax, D. M., Kim, R., Ryan, M., & Karchin, R. (2015) · Human Mutation · doi:10.1002/humu.22911 · Cited by 163
Li, M. M., Chao, E., Esplin, E. D., Miller, D. T., Nathanson, K. L., Plon, S. E., Scheuner, M. T., & Stewart, D. R. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0783-8 · Cited by 104
Self-citationThe Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine
Dickson, D. J., Johnson, J. E., Bergan, R. C., Owens, R., Subbiah, V., & Kurzrock, R. (2020) · Cell · doi:10.1016/j.cell.2019.12.009 · Cited by 80
ClinGen Allele Registry links information about genetic variants
Pawliczek, P., Patel, R. Y., Ashmore, L., Jackson, A. R., Bizon, C., Nelson, T. H., Powell, B. C., Freimuth, R. R., Strande, N. T., Shah, N., et al. (2018) · Human Mutation · doi:10.1002/humu.23637 · Cited by 63
Self-citationŠolman, M., Ligabue, A., Blaževitš, O., Jaiswal, A., Zhou, Y., Hong, L., Lectez, B. L. P., Kopra, K., Guzmán, C., Härmä, H., et al. (2015) · eLife · doi:10.7554/elife.08905 · Cited by 52
MutSpliceDB: A database of splice sites variants with RNA‐seq based evidence on effects on splicing
Palmisano, A., Vural, S., Zhao, Y., & Sonkin, D. (2021) · Human Mutation · doi:10.1002/humu.24185 · Cited by 19
Self-citation
Cited by
Cancer treatments: Past, present, and future
Sonkin, D., Thomas, A., & Teicher, B. A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.06.002 · Cited by 548
Self-citationClinVar: updates to support classifications of both germline and somatic variants
Landrum, M. J., Chitipiralla, S., Kaur, K., Brown, G., Chen, C., Hart, J., Hoffman, D., Jang, W., Liu, C., Maddipatla, Z., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1090 · Cited by 182
Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Somatic Mutations in HLA Class Genes and Antigen-Presenting Molecules in Malignant Glioma
Schulte, S. C., Peter, W., Rosenberger, G., Schäfer, M., Maire, C. L., Rünger, A., Ryba, A., Riecken, K., Fita, K. D., Matschke, J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0419 · Cited by 3
Metadata
- Authors
- Horak, P., Griffith, M., Danos, A. M., Pitel, B. A., Madhavan, S., Liu, X., Chow, C., Williams, H., Carmody, L., Barrow-Laing, L., Rieke, D., Kreutzfeldt, S., Stenzinger, A., Tamborero, D., Benary, M., Rajagopal, P. S., Ida, C. M., Lesmana, H., Satgunaseelan, L., Merker, J. D., Tolstorukov, M. Y., Campregher, P. V., Warner, J. L., Rao, S., Natesan, M., Shen, H., Venstrom, J., Roy, S., Tao, K., Kanagal-Shamanna, R., Xu, X., Ritter, D. I., Pagel, K., Krysiak, K., Dubuc, A., Akkari, Y. M., Li, X. S., Lee, J., King, I., Raca, G., Wagner, A. H., Li, M. M., Plon, S. E., Kulkarni, S., Griffith, O. L., Chakravarty, D., & Sonkin, D.
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 24
- Issue
- 5
- Pages
- 986-998
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W4210412949
- Cited by
- 257
- References
- 42
- FWCI
- 26.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.